Peptides for libido: what the evidence supports

Peptides for libido are peptide-based therapies studied for sexual desire, arousal, or function. The category is broad and uneven. One peptide, bremelanotide (PT-141), is FDA-approved for a specific form of low desire in premenopausal women. Others, such as kisspeptin and oxytocin, are at an earlier stage, with small studies and mixed results. Several peptide-adjacent therapies act on the hormonal axis rather than on desire directly.

Low libido is rarely a single-cause problem. Desire, arousal, and erectile or orgasmic function are separate processes, and each can be affected by hormones, cardiovascular and metabolic health, medications (antidepressants are a common culprit), relationship factors, stress, and mood. A peptide is not a substitute for that evaluation. The first step is usually a history, a medication review, and, where indicated, a hormone panel — see what to test before TRT and the women's hormone panel.

Bremelanotide, better known as PT-141, is the anchor of this category. It is a melanocortin receptor agonist that acts centrally — on desire pathways in the brain — rather than on blood flow the way PDE5 inhibitors do. The FDA approved it in 2019 as Vyleesi for acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women.

Vyleesi is labeled at 1.75 mg injected subcutaneously at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than 8 doses per month. The most common side effect in trials was nausea; focal hyperpigmentation has also been reported; flushing, headache, and a transient rise in blood pressure were also reported, and it is contraindicated in uncontrolled hypertension and known cardiovascular disease. Because PT-141 is an approved drug, compounding "essentially copies" of it is restricted; any compounded use is off-label and should be confirmed with the compounding partner.

Mechanism, research, and safety are covered on the PT-141 library page. The women's-health angle, including use outside the approved indication, is in PT-141 for women, and PT-141 vs Viagra and Cialis compares it with PDE5 inhibitors.

Kisspeptin is the hypothalamic signal that drives GnRH and, downstream, LH, FSH, and testosterone. Beyond hormones, small brain-imaging studies suggest it changes how the brain responds to sexual cues, including in people with low desire. That is promising mechanistic research, not an established libido treatment, and there is no established outpatient dose.

Oxytocin is released during sexual activity and orgasm, which made intranasal oxytocin an obvious candidate. Small trials of oxytocin nasal spray for sexual function have produced mixed results. In the US, oxytocin is FDA-approved only as an injection for obstetric use; intranasal use is off-label.

For men, it helps to separate desire from erectile function. Erectile dysfunction is most often vascular, and PDE5 inhibitors such as sildenafil and tadalafil remain the established first-line treatment. Our clinical overview of erectile dysfunction covers the causes and evaluation; PT-141 is discussed there as a centrally acting option studied where desire and arousal are the primary problem.

Low testosterone can reduce libido, so the hormonal axis is often part of the picture — see low testosterone symptoms. Men who want to protect fertility need options that work through, rather than suppress, their own axis: HCG acts directly on the testes, enclomiphene raises LH and FSH by blocking estrogen feedback (see enclomiphene and kisspeptin in practice), and fertility-preserving testosterone optimization compares the approaches. Testagen vs TRT covers the peptide bioregulator angle. The full men's program is on our men's health page.

For women, the approved peptide option is PT-141 (Vyleesi) for premenopausal HSDD. Desire changes around perimenopause and menopause are common and often hormonal, and evaluation of the broader hormonal picture usually comes before, or alongside, any peptide. See PT-141 for women, peptide therapy for menopause symptoms, and our women's health page.